This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Demoulin, J.-B. Articles by Renauld, J.-C. Search for Related Content PubMed PubMed Citation Articles by Demoulin, J.-B. Articles by Renauld, J.-C.

STAT5 Activation Is Required for Interleukin-9-dependent Growth and Transformation of Lymphoid Cells¹

Ludwig Institute for Cancer Research and the Experimental Medicine Unit of the Université Catholique de Louvain, B-1200 Brussels, Belgium [J-B. D., C. U., D. L., J-C. R.]; Institute for Biomedical Research, D-60596 Frankfurt/Main, Germany [B. G.]; and Department of Surgery, University of British Columbia, Jack Bell Research Centre, Vancouver Hospital and Health Sciences Centre, Vancouver, British Columbia, V6H 3Z6 Canada [A. M.]

Interleukin-9 (IL-9) is a growth factor for T cells and various hematopoietic and lymphoid tumor cells. IL-9 signaling involves activation of Janus kinase (JAK)1 and JAK3 kinases, and signal transducer and activator of transcription (STAT)1, STAT3 and STAT5. Using a dominant negative form of STAT5 (STAT5), we demonstrated that this factor is an important mediator of IL-9-dependent Ba/F3 cell growth. Mutation of the STAT binding site of the IL-9 receptor (tyr116phe) results in an important decrease in STAT activation and inhibition of proliferation in the presence of IL-9. A small number of cells escape this inhibition, and IL-9-dependent cell lines could be derived. The selected cells required activation of STAT5 for growth, which was blocked by STAT5 expression and enhanced by overexpression of wild-type STAT5. In contrast to parental cells, Ba/F3-Phe116 cells growing in the presence of IL-9 further progress to cytokine-independent tumorigenic clones. These tumorigenic clones exhibited a strong cytokine-independent activation of JAK1 and STAT5, which most likely supports their proliferation. Transfection of a constitutively activated variant of STAT5 promoted the growth of wild-type Ba/F3 cells in the absence of cytokine. Finally, the expression of the proto-oncogene pim-1 was correlated with STAT5 activation and cell growth. Our data suggest that STAT5 is an important mediator of IL-9-driven proliferation and that dysregulation of STAT5 activation favors tumorigenesis of lymphoid cells.

This article has been cited by other articles:

				T. G. Jones, J. Hallgren, A. Humbles, T. Burwell, F. D. Finkelman, P. Alcaide, K. F. Austen, and M. F. Gurish Antigen-Induced Increases in Pulmonary Mast Cell Progenitor Numbers Depend on IL-9 and CD1d-Restricted NKT Cells J. Immunol., October 15, 2009; 183(8): 5251 - 5260. [Abstract] [Full Text] [PDF]

				W. Elyaman, E. M. Bradshaw, C. Uyttenhove, V. Dardalhon, A. Awasthi, J. Imitola, E. Bettelli, M. Oukka, J. van Snick, J.-C. Renauld, et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells PNAS, August 4, 2009; 106(31): 12885 - 12890. [Abstract] [Full Text] [PDF]

				T. Hornakova, J. Staerk, Y. Royer, E. Flex, M. Tartaglia, S. N. Constantinescu, L. Knoops, and J.-C. Renauld Acute Lymphoblastic Leukemia-associated JAK1 Mutants Activate the Janus Kinase/STAT Pathway via Interleukin-9 Receptor {alpha} Homodimers J. Biol. Chem., March 13, 2009; 284(11): 6773 - 6781. [Abstract] [Full Text] [PDF]

				M. Nakasato, Y. Shirakura, M. Ooga, M. Iwatsuki, M. Ito, S.-i. Kageyama, S. Sakai, M. Nagata, and F. Aoki Involvement of the STAT5 Signaling Pathway in the Regulation of Mouse Preimplantation Development Biol Reprod, October 1, 2006; 75(4): 508 - 517. [Abstract] [Full Text] [PDF]

				L. Qiu, R. Lai, Q. Lin, E. Lau, D. M. Thomazy, D. Calame, R. J. Ford, L. W. Kwak, R. A. Kirken, and H. M. Amin Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells Blood, October 1, 2006; 108(7): 2407 - 2415. [Abstract] [Full Text] [PDF]

				K. J. Peltola, K. Paukku, T. L. T. Aho, M. Ruuska, O. Silvennoinen, and P. J. Koskinen Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3 Blood, May 15, 2004; 103(10): 3744 - 3750. [Abstract] [Full Text] [PDF]

				E. Iavnilovitch, B. Groner, and I. Barash Overexpression and Forced Activation of Stat5 in Mammary Gland of Transgenic Mice Promotes Cellular Proliferation, Enhances Differentiation, and Delays Postlactational Apoptosis Mol. Cancer Res., November 1, 2002; 1(1): 32 - 47. [Abstract] [Full Text] [PDF]

				R. Buettner, L. B. Mora, and R. Jove Activated STAT Signaling in Human Tumors Provides Novel Molecular Targets for Therapeutic Intervention Clin. Cancer Res., April 1, 2002; 8(4): 945 - 954. [Abstract] [Full Text] [PDF]

				N. Zhu, L. M. Ramirez, R. L. Lee, N. S. Magnuson, G. A. Bishop, and M. R. Gold CD40 Signaling in B Cells Regulates the Expression of the Pim-1 Kinase Via the NF-{kappa}B Pathway J. Immunol., January 15, 2002; 168(2): 744 - 754. [Abstract] [Full Text] [PDF]

				J.-B. Demoulin, J. Van Snick, and J.-C. Renauld Interleukin-9 (IL-9) Induces Cell Growth Arrest Associated with Sustained Signal Transducer and Activator of Transcription Activation in Lymphoma Cells Overexpressing the IL-9 Receptor Cell Growth Differ., March 1, 2001; 12(3): 169 - 174. [Abstract] [Full Text]